Anti-VEGF treatment strategies for wet AMD

Jaclyn L. Kovach; Stephen G. Schwartz; Harry W. Flynn; Ingrid U. Scott

doi:10.1155/2012/786870

Anti-VEGF treatment strategies for wet AMD

Jaclyn L. Kovach, Stephen G. Schwartz, Harry W. Flynn, Ingrid U. Scott

Research output: Contribution to journal › Review article › peer-review

176 Scopus citations

Abstract

Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become a standard treatment for neovascular age-related macular degeneration (AMD). During this time, treatment strategies have evolved from a monthly dosing schedule to individualized regimens. This paper will review the currently available anti-VEGF agents and evidence-based treatment strategies.

Original language	English (US)
Article number	786870
Journal	Journal of Ophthalmology
Volume	2012
DOIs	https://doi.org/10.1155/2012/786870
State	Published - 2012

All Science Journal Classification (ASJC) codes

Ophthalmology

Access to Document

10.1155/2012/786870

Cite this

@article{9f21612465ce43c39efc097d78274a3b,

title = "Anti-VEGF treatment strategies for wet AMD",

abstract = "Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become a standard treatment for neovascular age-related macular degeneration (AMD). During this time, treatment strategies have evolved from a monthly dosing schedule to individualized regimens. This paper will review the currently available anti-VEGF agents and evidence-based treatment strategies.",

author = "Kovach, {Jaclyn L.} and Schwartz, {Stephen G.} and Flynn, {Harry W.} and Scott, {Ingrid U.}",

year = "2012",

doi = "10.1155/2012/786870",

language = "English (US)",

volume = "2012",

journal = "Journal of Ophthalmology",

issn = "2090-004X",

publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Anti-VEGF treatment strategies for wet AMD

AU - Kovach, Jaclyn L.

AU - Schwartz, Stephen G.

AU - Flynn, Harry W.

AU - Scott, Ingrid U.

PY - 2012

Y1 - 2012

N2 - Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become a standard treatment for neovascular age-related macular degeneration (AMD). During this time, treatment strategies have evolved from a monthly dosing schedule to individualized regimens. This paper will review the currently available anti-VEGF agents and evidence-based treatment strategies.

AB - Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become a standard treatment for neovascular age-related macular degeneration (AMD). During this time, treatment strategies have evolved from a monthly dosing schedule to individualized regimens. This paper will review the currently available anti-VEGF agents and evidence-based treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=84869225440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869225440&partnerID=8YFLogxK

U2 - 10.1155/2012/786870

DO - 10.1155/2012/786870

M3 - Review article

C2 - 22523653

AN - SCOPUS:84869225440

SN - 2090-004X

VL - 2012

JO - Journal of Ophthalmology

JF - Journal of Ophthalmology

M1 - 786870

ER -

Anti-VEGF treatment strategies for wet AMD

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this